These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27019002)

  • 1. LSD1 inhibitors: a patent review (2010-2015).
    Stazi G; Zwergel C; Valente S; Mai A
    Expert Opin Ther Pat; 2016 May; 26(5):565-80. PubMed ID: 27019002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).
    Valente S; Mai A
    Expert Opin Ther Pat; 2014 Apr; 24(4):401-15. PubMed ID: 24397271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
    Zhou C; Kang D; Xu Y; Zhang L; Zha X
    Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
    Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
    Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances toward LSD1 inhibitors for cancer therapy.
    Fu X; Zhang P; Yu B
    Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends of LSD1 inhibitors in viral infections.
    Zwergel C; Stazi G; Mai A; Valente S
    Future Med Chem; 2018 May; 10(10):1133-1136. PubMed ID: 29787289
    [No Abstract]   [Full Text] [Related]  

  • 9. LSD1 inhibition: a therapeutic strategy in cancer?
    Lynch JT; Harris WJ; Somervaille TC
    Expert Opin Ther Targets; 2012 Dec; 16(12):1239-49. PubMed ID: 22957941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
    Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
    Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging approaches for histone deacetylase inhibitor drug discovery.
    Zwergel C; Valente S; Jacob C; Mai A
    Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress of LSD1-based dual-target agents for cancer therapy.
    Yang X
    Bioorg Med Chem; 2024 Mar; 101():117651. PubMed ID: 38401457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal chemistry insights in the discovery of novel LSD1 inhibitors.
    Wang X; Huang B; Suzuki T; Liu X; Zhan P
    Epigenomics; 2015; 7(8):1379-96. PubMed ID: 26646727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
    Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LSD1 inhibitors for anticancer therapy: a patent review (2017-present).
    Lv YX; Tian S; Zhang ZD; Feng T; Li HQ
    Expert Opin Ther Pat; 2022 Sep; 32(9):1027-1042. PubMed ID: 35914778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.